TABLE 2.
Drug-resistance mutations with corresponding MICs for nine anti-tuberculous drugsa
| Drug (breakpoint) | Gene | Mutation | MIC (μg/mL) | |||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Isoniazide (0.2 μg/mL) | 0.03 | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | ||
| katG | S315T/S315N | 1 | 3 | 11 | 54 | 51 | ||||
| Other | 1 | 1 | 2 | |||||||
| inhA | C−15T | 1 | 4 | 3 | ||||||
| Other | 1 | 1 | ||||||||
| ahpC | ahpC promoter mutation | 1 | 1 | |||||||
| katG and inhA | katG 315 and inhA promoter mutation | 11 | ||||||||
| Other | 1 | 1 | 2 | |||||||
| katG and ahpC | katG frameshift and ahpC C−72T | 1 | ||||||||
| ND | 1 | 1 | ||||||||
| Rifampicin (1 μg/mL) | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | ||
| rpoB | S450L/S450W/S450F | 94 | ||||||||
| H445Y/H445D/H445L/H445N/H445R/H445S | 3 | 1 | 1 | 13 | ||||||
| D435V/D435F | 1 | 1 | 4 | |||||||
| Other single mutation | 3 | 1 | 1 | |||||||
| S450L and other | 1 | 10 | ||||||||
| L430P and other | 2 | 10 | ||||||||
| Other multiple mutations | 1 | 1 | 5 | |||||||
| ND | 1 | |||||||||
| Ethambutol (5 μg/mL) | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | |||
| embB | M306V/M306I/M306L | 12 | 27 | 25 | 3 | |||||
| G406A/G406S/G406D | 1 | 1 | 4 | 9 | 2 | |||||
| Q497R/Q497K | 1 | 6 | 3 | |||||||
| Other single mutation | 1 | 1 | 1 | 1 | ||||||
| M306I and G406D/D354A/G406A/Q497R | 3 | 1 | ||||||||
| embA | Promoter mutation | 1 | 2 | |||||||
| embA and embB | embA promoter and embB mutation | 3 | 7 | 1 | ||||||
| ND | 9 | 16 | 9 | 2 | 2 | |||||
| Moxifloxacin (0.5 μg/mL) | 0.06 | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | ||
| gyrA | D94G/D94A/D94N/D94H/D94Y | 1 | 1 | 5 | 10 | 14 | 9 | 1 | ||
| A90V | 1 | 4 | 12 | 8 | ||||||
| S91P | 3 | 1 | ||||||||
| A90V and D94G | 1 | |||||||||
| gyrB | A504V | 1 | ||||||||
| gyrA and gyrB | gyrA 94 and gyrB mutation | 1 | 2 | |||||||
| gyrA H70R and gyrB E501D | 1 | |||||||||
| ND | 13 | 41 | 19 | 3 | 1 | 1 | ||||
| Streptomycin (2 μg/mL) | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | 32 | ||
| rpsL | K43R | 73 | ||||||||
| K88R | 1 | 1 | 3 | 3 | 5 | 4 | ||||
| rrs | A514C | 4 | 4 | 1 | 1 | |||||
| Other | 1 | 1 | 1 | |||||||
| gid | gid mutation | 4 | ||||||||
| rpsL and rrs | rpsL and rrs mutation | 1 | 4 | |||||||
| rpsL and gid | rpsL K43R and gid 115_del_G | 1 | ||||||||
| ND | 23 | 8 | 6 | 3 | 1 | |||||
| Amikacin (4 μg/mL) | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | ||
| rrs | A1401G | 13 | ||||||||
| ND | 3 | 68 | 64 | 5 | 1 | |||||
| Kanamycin (5 μg/mL) | 0.6 | 1.2 | 2.5 | 5 | 10 | 20 | 40 | |||
| rrs | A1401G | 13 | ||||||||
| eis | Promoter mutation | 1 | 1 | 4 | 1 | |||||
| ND | 14 | 98 | 22 | |||||||
| Ethionamide (5 μg/mL) | 0.3 | 0.6 | 1.25 | 2.5 | 5 | 10 | 20 | 40 | ||
| ethA | Frameshift | 1 | 6 | 2 | 1 | 1 | ||||
| Other | 1 | 1 | ||||||||
| inhA | I21T | 1 | ||||||||
| fabG1 | C−15T | 1 | 3 | 5 | 1 | 5 | ||||
| T−8C | 2 | |||||||||
| fabG1 and ethA | fabG1 C−15T and ethA frameshift | 3 | ||||||||
| fabG1 and InhA | fabG1 C−15T and InhA I21T | 1 | 2 | |||||||
| ND | 28 | 63 | 14 | 5 | 4 | 1 | ||||
| Rifabutin (0.5 μg/mL) | 0.12 | 0.25 | 0.5 | 1 | 2 | 4 | 8 | 16 | ||
| rpoB | S450L/S450W/S450F | 2 | 18 | 13 | 24 | 23 | 9 | 5 | ||
| H445Y/H445D/H445L/H445N/H445R/H445S | 1 | 4 | 4 | 2 | 3 | 1 | 2 | |||
| D435F/D435V | 2 | 1 | 2 | 1 | ||||||
| Other single mutation | 2 | 1 | 1 | 1 | ||||||
| S450L and other | 3 | 2 | 1 | 4 | 1 | |||||
| L430P and other | 1 | 1 | 1 | 3 | 1 | 4 | 1 | |||
| Other multiple mutations | 1 | 1 | 3 | 1 | 1 | |||||
| ND | 1 | |||||||||
aThe numbers indicate the number of strains with this MIC. The numbers in bold type indicate resistance MICs above the breakpoint, shown in parentheses. ND, no resistance mutations detected.